The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Recommendations for Sjögren’s Syndrome: How to Address Biologics & Musculoskeletal Pain

Recommendations for Sjögren’s Syndrome: How to Address Biologics & Musculoskeletal Pain

April 2, 2017 • By Arthritis Care & Research

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Affecting up to 3.1 million Americans, Sjögren’s syndrome is an under-recognized autoimmune disorder associated with a high burden of illness, diminished quality of life and increased healthcare costs. In response to patients’ requests for improved care and physicians’ requests for guidance, the Sjögren’s Syndrome Foundation (SSF) developed clinical practice guidelines, partnering with the American College of Rheumatology (ACR) Quality of Care Committee and staff. Key stakeholders, who include patients and practicing and academic rheumatologists, were brought together. Working groups reviewed scientific literature about the rheumatologic/systemic, ocular and oral manifestations of the disease and developed consensus, resulting in evidence-based recommendations.

You Might Also Like
  • Clinical Guidelines for Sjögren’s Syndrome Focus on Biologics, Fatigue, Inflammatory Musculoskeletal Pain
  • New Osteoarthritis Recommendations and Classification Criteria for Sjögren’s Syndrome and Polymyalgia Rheumatica
  • Patient Fact Sheet: Sjögren’s Syndrome

“These first-ever standard-of-care guidelines for systemic Sjögren’s syndrome in the U.S. will improve consistency in practice patterns, inform coverage and reimbursement policies, lead to the design and implementation of needed educational programs, highlight areas for future research, and—most importantly—fill a significant clinical void,” write Steven E. Carsons, MD, of Winthrop-University Hospital Campus, State University of New York, Stony Brook, and his colleagues in their article published in the April 2017 issue of Arthritis Care & Research.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In total, the SSF achieved consensus on 19 recommendations—with 11 additional modules for which data were insufficient for the creation of a formal recommendation. However, because no curative or remittive agent currently exists for Sjögren’s syndrome, therapeutic goals remain symptom palliation, improved quality of life, the prevention of damage and the appropriate selection of patients for immunosuppressive therapy.

In the article, Dr. Carsons and colleagues outline the guidelines development process and discuss three rheumatologic topics with recommendations: biologic therapy, fatigue management and the use of disease-modifying anti-rheumatic drugs (DMARDs) for inflammatory musculoskeletal pain.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Biologic Agents for Sicca & Systemic Manifestations
Tumor necrosis factor (TNF) inhibitors: The guidelines strongly recommend against the use of TNF inhibitors to treat sicca symptoms in patients with primary Sjögren’s syndrome. However, “this recommendation should not be interpreted to discourage use of TNF inhibitors in situations [in which] there is overlap with RA [rheumatoid arthritis] or [in which] TNF inhibition therapy is indicated for the treatment of inflammatory arthritis,” write the authors.

Rituximab: Based on multiple randomized clinical trials, rituximab is recommended as a possible therapy for keratoconjunctivitis sicca and xerostomia in patients with primary Sjögren’s syndrome for whom conventional therapies have proved insufficient. The treatment is also an option for patients with Sjögren’s syndrome and the following systemic manifestations: vasculitis, with or without cryoglobulinemia, severe parotid swelling, inflammatory arthritis, pulmonary disease and peripheral neuropathy.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: Arthritis Care & Research, Clinical Practice Guidelines, fatigue, Musculoskeletal, rituximab, sicca, Sjögren's syndrome

You Might Also Like:
  • Clinical Guidelines for Sjögren’s Syndrome Focus on Biologics, Fatigue, Inflammatory Musculoskeletal Pain
  • New Osteoarthritis Recommendations and Classification Criteria for Sjögren’s Syndrome and Polymyalgia Rheumatica
  • Patient Fact Sheet: Sjögren’s Syndrome
  • Rituximab for Fatigue & Oral Dryness in Primary Sjögren’s Syndrome

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.